RTOG Foundation Study 3502

Status Date:  January 03, 2020  | Status:  Closed to Accrual


A Randomized Phase II Trial In Patients With Operable Stage I Non-Small Cell Lung Cancer: Radical Resection Versus Ablative Stereotactic Radiotherapy

Principal Investigators

China: Jinming Yu, MD, PhD
U.S.: Feng-Ming (Spring) Kong, MD, PhD

Primary Objective

To determine whether SBRT provides local-regional tumor control that is not more than 15% lower than RODS.

Patient Population

Patients must have histologically proven CT and PET-CT confirmed Stage I, T1N0M0 non-small cell lung cancer.

Participating Sites

Institution Name City State/Country
Chinese Academy of Medical Sciences Beijing China
Shandong Cancer Hospital Jinan Shandong, China
Shanghai Cancer Center/Fudan University Shanghai China
Zhejiang Cancer Hospital Hangzhou Zhejiang, China

Participate in RTOG Research

To participate as an RTOG study investigator, your organization must be part of the RTOG Foundation network. Patients who wish to participate in a study must be under the care of an RTOG participating investigator. For additional information, email info@rtog.org or call 1-215-574-3173.

See our clinical trials